PERCANS ONCOLOGY
Percans Oncology is a pharmaceutical company specializing in the field of anticancer drug development.
PERCANS ONCOLOGY
Social Links:
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2012-11-01
Address:
Changping, Beijing, China
Country:
China
Website Url:
http://www.zkbymed.com
Total Employee:
51+
Status:
Active
Contact:
400-164-8199
Email Addresses:
[email protected]
Total Funding:
85 M CNY
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Apple Mobile Web Clips Icon Content Delivery Network Apache Mobile Non Scaleable Content Nginx Apache 2.4 DigiCert SSL
Similar Organizations
Cann10
Cann10 is an international pharmaceutical company specializing in the field of medical cannabis.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Current Employees Featured
Founder
Investors List
Juxin Ziben
Juxin Ziben investment in Series B - Percans Oncology
Chengyu Touzi Youxian Gongsi
Chengyu Touzi Youxian Gongsi investment in Series B - Percans Oncology
Legend Star
Legend Star investment in Series B - Percans Oncology
Kind Help
Kind Help investment in Series B - Percans Oncology
Pan-Lin Capital
Pan-Lin Capital investment in Series B - Percans Oncology
Legend Star
Legend Star investment in Series A - Percans Oncology
Legend Star
Legend Star investment in Series A - Percans Oncology
Legend Capital
Legend Capital investment in Series A - Percans Oncology
Official Site Inspections
http://www.zkbymed.com
- Host name: 47.94.226.112
- IP address: 47.94.226.112
- Location: Hangzhou China
- Latitude: 30.294
- Longitude: 120.1619
- Timezone: Asia/Shanghai
More informations about "Percans Oncology"
智康博药
科赛瑞在Myc 突变肿瘤上布局的第二个化合物是zotiraciclib (ZTR/TG02)。 ZTR 是一种高效的口服 CDK9 抑制剂，能够穿过血脑屏障，并降解 Mcl-1 和 Myc这类半衰期短、抗凋亡致癌基因的蛋白质。See details»
Cothera Bioscience
Cothera Bioscience was formed by the founding core members of CrownBio, a well-known Contract Research Organization specializing in translational oncology, to develop innovative, targeted cancer therapies. Cothera Bioscience has …See details»
Percans Oncology - Crunchbase Company Profile
Organization. Percans Oncology . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email …See details»
Company introduction - en.zkbymed.com
Cothera Bioscience was formed by the founding core members of CrownBio, a well-known Contract Research Organization specializing in translational oncology, to develop innovative, …See details»
领导团队 - zkbymed.com
科赛睿（Cothera）生命科学公司联合创始人兼CEOSee details»
About Us - en.zkbymed.com
WeChat official account Copyright 2015 Beijing zhikangbo Medical Oncology Research Co., Ltd 京公网安备 11011402013345号 京公网安备 11011402013345号See details»
北京智康博药肿瘤医学研究有限公司 | LinkedIn
北京智康博药肿瘤医学研究有限公司 | 17 followers on LinkedIn. 北京智康博药肿瘤医学研究有限公司是一家专门从事个体化肿瘤治疗研究的精准医疗服务 ...See details»
Beijing Percans Oncology Co., Ltd. (北京智康博药肿瘤医学研究有 …
了解Beijing Percans Oncology Co., Ltd. (北京智康博药肿瘤医学研究有限公司)公司的药物管线，治疗领域，技术平台，以及它的1项临床试, 7篇新闻和4篇文献，疾病领域:肿瘤，神经系统疾 …See details»
Beijing Percans Oncology Research - ZoomInfo
Who is Beijing Percans Oncology Research. Beijing Percans Oncology Research Co. Ltd is a company that operates in the Biotechnology industry. It employs 51-100 people and has …See details»
企业文化 - zkbymed.com
在肿瘤药物研发领域，以转化医学为手段，聚焦于以“孤儿症”靶点为主的难治性肿瘤适应症，寻找更有效的组合致死治疗方案，帮助肿瘤患者减少痛苦，提高生命质量。See details»
智康博药-北京智康博药肿瘤医学研究有限公司-企业详情-InvestGO …
查看医药魔方InvestGO®数据库智康博药的公司信息。智康博药（北京智康博药肿瘤医学研究有限公司），公司简介：北京智康博药肿瘤医学研究有限公司是一家专门从事肿瘤个体化治疗研究 …See details»
智康博药-动脉网 - vbdata.cn
Nov 1, 2012 智康博药是一家针对肿瘤患者提供个体化治疗方案的医疗服务公司，通过自己独特的 I-GraftTM 技术平台为每一位肿瘤患者寻找最有效治疗方案，延长和挽救患者生命。See details»
智康博药-个体化肿瘤治疗数据库系统
智康博药-个体化肿瘤治疗数据库系统See details»
Company culture - en.zkbymed.com
Aim for the field of oncology medical research and development, take the advantage of translational medicine, focus on orphan drugs mainly for refractory tumor indications, find more …See details»
智康博药 | 项目信息-36氪
智康博药是一家针对肿瘤患者提供个体化治疗方案的医疗服务公司，通过自己独特的 I-GraftTM 技术平台为每一位肿瘤患者寻找最有效治疗方案，延长和挽救患者生命。See details»
新闻详情页 - zkbymed.com
近日，智康博药母公司科赛睿生物（Cothera Bioscience）完成近3000万美元B轮融资。本轮融资由清松资本领投，招银国际、夏尔巴投资、新世界投资、朗盛投资、昆仑资本、Harbinger …See details»
新闻详情页 - zkbymed.com
智康博药完成2500万a轮融资 君联资本联想之星投资. 2015年9月15日联想控股旗下的风险投资基金君联资本宣布联合联想控股旗下的联想之星完成对北京智康博药肿瘤医学研究有限公 …See details»
News - en.zkbymed.com
PC-002 International Multicenter Phase II Clinical Trial in Beijing Cancer Hospital Launches Patient RecruitmentSee details»
体外药敏监测 - zkbymed.com
PrimeGro®培养基是基于智康博药的i-CR条件性细胞重编程技术（ConditionalReprogramming）原理而自主研发的新一代细胞培养基，适用于大多数上皮细胞来源的原代肿瘤细胞培养。See details»
新闻详情页 - zkbymed.com
北京、旧金山，2021年9月27日，智康博药母公司科赛睿生物（Cothera Bioscience）今天宣布已经收到美国食 品药品监督管理局（FDA）的批准，同意其对靶向MYC蛋白的抑制剂PC-002开 …See details»